EUVIMEDEUVIMED entdecken
Crossref

Screening Plus Corneal Cross‐Linking for Keratoconus Is Cost‐Effective for New Zealand: A Proof‐of‐Concept Markov Analysis

Chuen Yen Hong, Sheng Chiong Hong, Graham Wilson

Clinical & Experimental Ophthalmology · 2025

DOI: 10.1111/ceo.14604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Chuen Yen Hong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health New Zealand Southern, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Keratoconus, Cross-Linking Reagents, Photochemotherapy, Collagen. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prevalence of keratoconus in New Zealand is higher compared to the global prevalence of 1.38 per 1000, with Māori and Pacific Islander being over‐represented. The form of keratoconus in New Zealand has been shown to have a more rapid progression of disease. In this study, we aimed to evaluate the cost‐effectiveness of introducing screening for keratoconus in the New Zealand context, with corneal cross‐linking as treatment for those screening positive.

Methods

A Markov simulation was used to model the impact of screening plus corneal cross‐linking compared to usual care across a lifetime horizon and societal perspective with a 3% discount rate. Cost‐effectiveness was determined by the incremental cost‐effectiveness ratio, with utility measured in quality‐adjusted life‐years. Univariate and probabilistic sensitivity analyses were carried out to investigate factors influencing cost‐effectiveness.

Results

The incremental cost‐effectiveness for screening with corneal cross‐linking treatment was ‐NZ$1278 (95% CI −1418, −1139) per QALY gained. Factors that had the most influence on incremental cost‐effectiveness were the specificity of the screening test, the prevalence of keratoconus at the time of screening, the discount rate, the probability of patients who are progressors, adherence, and efficacy of cross‐linking treatment.

Conclusion

Screening for keratoconus at age 15 with corneal cross‐linking treatment for children who screened positive is likely to be cost saving. Our results support the need for a real‐world trial and cost‐effectiveness analysis in New Zealand to ensure that we identify and treat those at risk early in the disease course before significant vision loss has occurred.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratoconusCross-Linking ReagentsPhotochemotherapyCollagenMass ScreeningCorneal StromaHumansCost-Benefit AnalysisNew ZealandMarkov ChainsQuality-Adjusted Life YearsPhotosensitizing AgentsRiboflavinUltraviolet RaysMalePrevalenceAdultHealth Care CostsFemaleAdolescentCorneal Cross-Linking

Stichwörter der Autor:innen

corneal cross‐linkingcost‐effectiveness analysiskeratoconusmass screening

Substanzen

Photosensitizing AgentsCross-Linking ReagentsRiboflavinCollagen

Autor:innen und Institutionen

  • Health New Zealand Southern, Dunedin, New Zealand.
  • oDocs Eye Care, Dunedin, New Zealand.
  • Health New Zealand Tairawhiti, Gisborne, New Zealand.

Zitieren

APA

Hong, C. Y., Hong, S. C., & Wilson, G. (2025). Screening Plus Corneal Cross‐Linking for Keratoconus Is Cost‐Effective for New Zealand: A Proof‐of‐Concept Markov Analysis. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14604

Vancouver

Hong CY, Hong SC, Wilson G. Screening Plus Corneal Cross‐Linking for Keratoconus Is Cost‐Effective for New Zealand: A Proof‐of‐Concept Markov Analysis. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14604

BibTeX
@article{Hong2025,
  author = {Hong, Chuen Yen and Hong, Sheng Chiong and Wilson, Graham},
  title = {Screening Plus Corneal Cross‐Linking for Keratoconus Is Cost‐Effective for New Zealand: A Proof‐of‐Concept Markov Analysis},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  doi = {10.1111/ceo.14604}
}
Kostenlos starten →